Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Burlington, VT
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Burlington, VT
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Morgantown, WV
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Morgantown, WV
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer
Status: Archived
Providence Medical Center
mi
from
Portland, OR
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Providence Medical Center
mi
from
Portland, OR
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
McFarland Clinic, PC
mi
from
Ames, IA
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
mi
from
Ames, IA
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Med College of Georgia
mi
from
Augusta, GA
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Med College of Georgia
mi
from
Augusta, GA
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Providence Medical Group
mi
from
Terre Haute, IN
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Providence Medical Group
mi
from
Terre Haute, IN
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Texas Oncology-Abilene
mi
from
Abilene, TX
Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Texas Oncology-Abilene
mi
from
Abilene, TX
A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
Status: Archived
Clinical Research Facility
mi
from
Detroit, MI
A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Detroit, MI
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
A Randomized Phase II Trial of Docetaxel, Cisplatin, and Hypofractionated Radiotherapy Versus Docetaxel and Cisplatin for Limited Volume Stage IV Non-small Cell Lung Cancer: The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial
Status: Archived
University of Chicago
mi
from
Chicago, IL
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
A Randomized Phase II Trial of Docetaxel, Cisplatin, and Hypofractionated Radiotherapy Versus Docetaxel and Cisplatin for Limited Volume Stage IV Non-small Cell Lung Cancer: The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
A Phase I/II Study of RAD001 and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
A Phase I/II Study of RAD001 and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Franklin, TN
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
A Phase I/II Study of RAD001 and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Vanderiblt University Medical Center
mi
from
Nashville, TN
Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer
A Phase I/II Study of RAD001 and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
Vanderiblt University Medical Center
mi
from
Nashville, TN
Seamless Study Of Stereotactic Lung Radiotherapy (SBRT) For Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) In Medically Inoperable Patients
Seamless Phase I/II Study Of Stereotactic Lung Radiotherapy (SBRT) For Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) In Medically Inoperable Patients
Status: Archived
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Seamless Study Of Stereotactic Lung Radiotherapy (SBRT) For Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) In Medically Inoperable Patients
Seamless Phase I/II Study Of Stereotactic Lung Radiotherapy (SBRT) For Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) In Medically Inoperable Patients
Status: Archived
Updated: 1/1/1970
Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
Open Label Randomized Trial of Early Assessment of Therapy Response Using 18FDG-PET/CT in Patients With Marginally Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer (NSCLC) Treated With Induction Concurrent Chemoradiation Followed by Resection and Adjuvant Chemotherapy
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
Open Label Randomized Trial of Early Assessment of Therapy Response Using 18FDG-PET/CT in Patients With Marginally Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer (NSCLC) Treated With Induction Concurrent Chemoradiation Followed by Resection and Adjuvant Chemotherapy
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
GSK Investigational Site
mi
from
Indianapolis, IN
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Indianapolis, IN
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
GSK Investigational Site
mi
from
Westwood, KA
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Westwood, KA
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
GSK Investigational Site
mi
from
Chesterfield, MO
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Chesterfield, MO
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
GSK Investigational Site
mi
from
Las Vegas, NV
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Las Vegas, NV
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
GSK Investigational Site
mi
from
Kennewick, WA
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin or Cisplatin Plus Pemetrexed
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Kennewick, WA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Georgia Clinical Research
mi
from
Austell, GA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Georgia Clinical Research
mi
from
Austell, GA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Indiana University
mi
from
Indianapolis, IN
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Indiana University
mi
from
Indianapolis, IN
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Louisiana State University
mi
from
New Orleans, LA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Louisiana State University
mi
from
New Orleans, LA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
University of Missouri
mi
from
Columbia, MO
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
University of Missouri
mi
from
Columbia, MO
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
New York University
mi
from
New York, NY
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
New York University
mi
from
New York, NY
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Temple University
mi
from
Philadelphia, PA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Temple University
mi
from
Philadelphia, PA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Vanderbilt University Medical Center
mi
from
Ventura, CA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Ventura, CA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
University of Virginia
mi
from
Charlottesville, VA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: CLIA
Status: Archived
Updated: 1/1/1970
University of Virginia
mi
from
Charlottesville, VA
Tumor Markers in Lung Cancer
Tumor Markers in Lung Cancer
Status: Archived
Veterans Affairs Medical Center
mi
from
Oklahoma City, OK
Tumor Markers in Lung Cancer
Tumor Markers in Lung Cancer
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center
mi
from
Oklahoma City, OK
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck
Status: Archived
Loma Linda Medical Center
mi
from
Loma Linda, CA
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck
Status: Archived
Updated: 1/1/1970
Loma Linda Medical Center
mi
from
Loma Linda, CA
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
101 Carnegie Center
mi
from
Princeton, NJ
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.
Status: Archived
Updated: 1/1/1970
101 Carnegie Center
mi
from
Princeton, NJ
Biomarkers in the Evaluation of Chronic Lung Disease
Biomarkers in the Evaluation of Chronic Lung Disease
Status: Archived
Interstitial Lung Disease and Pulmonary Hypertension Programs
mi
from
New Hyde Park, NY
Biomarkers in the Evaluation of Chronic Lung Disease
Biomarkers in the Evaluation of Chronic Lung Disease
Status: Archived
Updated: 1/1/1970
Interstitial Lung Disease and Pulmonary Hypertension Programs
mi
from
New Hyde Park, NY
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-Small Cell Lung Cancer (NSCLC)
Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study
Status: Archived
Cancer Institute of New Jersey at Hamilton
mi
from
Trenton, NJ
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-Small Cell Lung Cancer (NSCLC)
Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study
Status: Archived
Updated: 1/1/1970
Cancer Institute of New Jersey at Hamilton
mi
from
Trenton, NJ
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-Small Cell Lung Cancer (NSCLC)
Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study
Status: Archived
Mountainside Hospital
mi
from
Montclair, NJ
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-Small Cell Lung Cancer (NSCLC)
Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study
Status: Archived
Updated: 1/1/1970
Mountainside Hospital
mi
from
Montclair, NJ
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-Small Cell Lung Cancer (NSCLC)
Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-Small Cell Lung Cancer (NSCLC)
Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ